Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 3,236 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Frequency, Urge Incontinence, Neurogenic Bladder
Interventions: Lidocaine 2% without vessel constrictor; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Trichotillomania (Hair-Pulling Disorder), Dermatillomania
Interventions: Placebo, Aripiprazole; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Concussion (Diagnosis), Concussion Post Syndrome, Concussion, Mild
Interventions: Brain Cooling; Device
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 27 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Hypoplastic Left Heart Syndrome
Interventions: Ventrix Bio Extracellular Matrix; Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 1 Year
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: PFAS, Environmental Exposures, Occupational Exposure to Chemicals, Military Exposure, Burn Pit Exposure, Forever Chemicals, Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia, Hyperlipidemia (E.G., Hypercholesterolemia)
Interventions: Colesevelam, Placebo; Drug
Lead sponsor: University of Rhode Island; Other
Eligibility: 25 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Louisville, Kentucky • Augusta, Maine

Conditions: Exercise Training and Sarcopenia
Interventions: Exercise; Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 60 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cardiovascular (CV) Risk
Interventions: Neqpiaput linruugut (Our Food is Medicine); Behavioral
Lead sponsor: University of Alaska Fairbanks; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Fairbanks, Alaska

Conditions: Depression Disorders, Anxiety Disorders
Interventions: Not listed
Lead sponsor: Deliberate Solutions Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Prevention
Interventions: Education and Mentoring for Prescribing Pharmacists; Other
Lead sponsor: Xavier University of Louisiana.; Other
Eligibility: 24 Years to 99 Years
Enrollment: 75 participants
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Stroke
Interventions: Exercise, Behavioral Management Program; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 89 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Non-diabetic Chronic Kidney Disease
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: HIV-1-infection
Interventions: VRC07-523LS, PGT121.414.LS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Aurora, Colorado + 7 more

Conditions: Progressive Pediatric Brain Cancer
Interventions: NLG802 (indoximod Prodrug), Temozolomide; Drug
Lead sponsor: Lumos Pharma; Industry
Eligibility: 5 Years to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Opioid Use Disorder
Interventions: Reentry Incentives and Support for Engagement with Contingency Management (RISE-CM) Intervention; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Warrenton, Oregon

Conditions: Long Term, Quality of Life, Recurrence Free, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy
Interventions: Questionnaire and Physical Exam; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gestatiaonl Diabetes Mellitus, Pregnancy, Diabetes in Pregnancy, Insulin Dependent Diabetes Mellitus, Insulin
Interventions: Injection Port for Insulin Administration, Single-Use Insulin Needles; Device
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthcare Professionals
Interventions: Narrative Medicine Workshop; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Autism, Neurodevelopment
Interventions: Automated AAC Assessment and Low-Tech AAC Implementation Support, Standard AAC Support; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 3 Years to 14 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Environmental Exposure
Interventions: Cholestyramine, Centrum; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Continuous Glucose Monitoring, Type 1 Diabetes, Type 2 Diabetes
Interventions: FreeStyle Libre 3 Plus Continuous Glucose Monitor; Device
Lead sponsor: University of the Pacific; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stockton, California

Conditions: Diabetes Mellitus Type 2
Interventions: DREAM; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Treatment Resistant Depression, Substance Use Disorders
Interventions: Psilocybin; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: PTSD - Post Traumatic Stress Disorder, Substance Use
Interventions: Adapted Cognitive Behavioral Intervention for Trauma in Schools (CBITS) with a Racial Trauma Module (RTM); Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
Interventions: Medical Device Usage and Evaluation, Tirzepatide; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Chicago, Illinois • Houston, Texas

Search by objective public record fields.

Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections

Aripiprazole in Body Focused Repetitive Behaviors

Female Concussion Head Cooling

Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS)

Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study

Time Efficient Exercise to Reverse Sarcopenia and Improve Cardio-metabolic Health

Neqpiaput Iinruugut (Our Food Is Medicine): A Tribally Driven Food Sovereignty Intervention to Reduce Heart Disease Risk in Alaska Native Adults

Validate the Temporal Stability and Responsiveness of AI-COA® for Depression and Anxiety

Are Louisiana Pharmacists PrEPared? Implementing Training and an Active PrEP (Pre-Exposure Prophylaxis) Prescribing Surveillance Program

Self-Managed Exercise in Chronic Stroke

Vascular Effects of SGLT2i in Non-diabetic CKD

A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection

Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer

Reentry Incentives and Support for Engagement With Contingency Management

Long-Term Quality Of Life And Symptom Assessment Among Recurrence-Free Patients Who Underwent Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Injection Ports vs Single-Use Needles for Insulin in Pregnancy: Effects on Adherence and Satisfaction

Narrative Medicine Effects on Burnout and Stress

Reciprocal Innovation to Optimize Low-Tech Augmentative and Alternative Communication (AAC) for Individuals

PFAS Clinical Trial

Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes

Developing Resiliency and Exercise Using AI-based Messaging

Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder

CBITS-RTM Pilot Study

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer